TORONTO, March 20, 2026 (GLOBE NEWSWIRE)-- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that St. Michael’s Hospital (SMH), part of Unity Health ...
The CS-AKI Phase II trial is an international multi-center, randomized, double-blind, placebo-controlled study of LSALT peptide with a recruitment target of 240 patients. The primary objective of the ...
Arch Biopartners Inc. (Arch) announced that St. Michael’s Hospital (SMH), part of Unity Health Toronto, has commenced patient dosing in Arch’s ongoing phase II trial evaluating LSALT peptide for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results